Vanguard Group Inc. boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,748,569 shares of the medical research company’s stock after buying an additional 406,901 shares during the period. Vanguard Group Inc. owned 9.83% of Edwards Lifesciences Corporation worth $2,453,311,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. South Texas Money Management Ltd. increased its position in Edwards Lifesciences Corporation by 2.5% in the second quarter. South Texas Money Management Ltd. now owns 353,598 shares of the medical research company’s stock worth $41,809,000 after buying an additional 8,782 shares during the period. D.A. Davidson & CO. increased its position in Edwards Lifesciences Corporation by 147.8% in the second quarter. D.A. Davidson & CO. now owns 23,911 shares of the medical research company’s stock worth $2,827,000 after buying an additional 14,263 shares during the period. Ithaka Group LLC increased its position in Edwards Lifesciences Corporation by 1.0% in the second quarter. Ithaka Group LLC now owns 133,902 shares of the medical research company’s stock worth $15,833,000 after buying an additional 1,290 shares during the period. UBS Asset Management Americas Inc. increased its position in Edwards Lifesciences Corporation by 6.4% in the second quarter. UBS Asset Management Americas Inc. now owns 611,062 shares of the medical research company’s stock worth $72,252,000 after buying an additional 36,936 shares during the period. Finally, Nicholas Investment Partners LP acquired a new stake in Edwards Lifesciences Corporation in the second quarter worth $5,904,000. 82.08% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the company. Stifel Nicolaus reissued a “buy” rating and issued a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a research note on Tuesday, July 18th. SunTrust Banks, Inc. increased their price target on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC increased their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $120.75.

In related news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction on Friday, September 15th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 182,501 shares of company stock valued at $20,847,236. 2.13% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/21/vanguard-group-inc-has-2-45-billion-holdings-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (EW) traded down 0.900% during trading on Thursday, hitting $110.715. The company had a trading volume of 196,419 shares. The company has a market capitalization of $23.38 billion, a price-to-earnings ratio of 33.581 and a beta of 0.64. The firm has a 50-day moving average of $113.80 and a 200 day moving average of $109.37. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.